224 related articles for article (PubMed ID: 20003214)
1. Combination antiretroviral drugs in PLGA nanoparticle for HIV-1.
Destache CJ; Belgum T; Christensen K; Shibata A; Sharma A; Dash A
BMC Infect Dis; 2009 Dec; 9():198. PubMed ID: 20003214
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.
Date AA; Shibata A; Goede M; Sanford B; La Bruzzo K; Belshan M; Destache CJ
Antiviral Res; 2012 Dec; 96(3):430-6. PubMed ID: 23041201
[TBL] [Abstract][Full Text] [Related]
3. Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment.
Shibata A; McMullen E; Pham A; Belshan M; Sanford B; Zhou Y; Goede M; Date AA; Destache CJ
AIDS Res Hum Retroviruses; 2013 May; 29(5):746-54. PubMed ID: 23289671
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice.
Destache CJ; Belgum T; Goede M; Shibata A; Belshan MA
J Antimicrob Chemother; 2010 Oct; 65(10):2183-7. PubMed ID: 20729545
[TBL] [Abstract][Full Text] [Related]
5. Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis.
Chaowanachan T; Krogstad E; Ball C; Woodrow KA
PLoS One; 2013; 8(4):e61416. PubMed ID: 23630586
[TBL] [Abstract][Full Text] [Related]
6. Preparation, characterization, and safety evaluation of poly(lactide-co-glycolide) nanoparticles for protein delivery into macrophages.
Guedj AS; Kell AJ; Barnes M; Stals S; Gonçalves D; Girard D; Lavigne C
Int J Nanomedicine; 2015; 10():5965-79. PubMed ID: 26445538
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.
Gupta SK; Rosenkranz SL; Cramer YS; Koletar SL; Szczech LA; Amorosa V; Hall SD
AIDS; 2008 Oct; 22(15):1919-27. PubMed ID: 18784455
[TBL] [Abstract][Full Text] [Related]
8. Noncovalent PEG Coating of Nanoparticle Drug Carriers Improves the Local Pharmacokinetics of Rectal Anti-HIV Microbicides.
Nunes R; Araújo F; Barreiros L; Bártolo I; Segundo MA; Taveira N; Sarmento B; das Neves J
ACS Appl Mater Interfaces; 2018 Oct; 10(41):34942-34953. PubMed ID: 30234288
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell-Cell HIV Transmission.
Jiang Y; Cao S; Bright DK; Bever AM; Blakney AK; Suydam IT; Woodrow KA
Mol Pharm; 2015 Dec; 12(12):4363-74. PubMed ID: 26529558
[TBL] [Abstract][Full Text] [Related]
10. pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission.
Zhang T; Sturgis TF; Youan BB
Eur J Pharm Biopharm; 2011 Nov; 79(3):526-36. PubMed ID: 21736940
[TBL] [Abstract][Full Text] [Related]
11. Developing combination of artesunate with paclitaxel loaded into poly-d,l-lactic-co-glycolic acid nanoparticle for systemic delivery to exhibit synergic chemotherapeutic response.
Tran BN; Nguyen HT; Kim JO; Yong CS; Nguyen CN
Drug Dev Ind Pharm; 2017 Dec; 43(12):1952-1962. PubMed ID: 28724314
[TBL] [Abstract][Full Text] [Related]
12. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance.
Zhang D; Kong YY; Sun JH; Huo SJ; Zhou M; Gui YL; Mu X; Chen H; Yu SQ; Xu Q
Int J Nanomedicine; 2017; 12():2081-2108. PubMed ID: 28356731
[TBL] [Abstract][Full Text] [Related]
13. Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico.
Sierra-Madero J; Villasis-Keever A; Méndez P; Mosqueda-Gómez JL; Torres-Escobar I; Gutiérrez-Escolano F; Juárez-Kasusky I; Magana-Aquino M; Ramos-Santos C; Pérez-Saleme L; Rangel-Frausto S; Antuna-Puente B; Soto-Ramírez LE; Lima V; Belaunzarán-Zamudio F; Crabtree-Ramírez B; Montaner J
J Acquir Immune Defic Syndr; 2010 Apr; 53(5):582-8. PubMed ID: 20090545
[TBL] [Abstract][Full Text] [Related]
14. Using microfluidic platforms to develop CNS-targeted polymeric nanoparticles for HIV therapy.
Martins C; Araújo F; Gomes MJ; Fernandes C; Nunes R; Li W; Santos HA; Borges F; Sarmento B
Eur J Pharm Biopharm; 2019 May; 138():111-124. PubMed ID: 29397261
[TBL] [Abstract][Full Text] [Related]
15. Preparation, characterization and uptake of PEG-coated, muco-inert nanoparticles in HGC-27 cells, a mucin-producing, gastric-cancer cell line.
Lin D; Li G; Qin L; Wen Z; Wang J; Sun X
J Biomed Nanotechnol; 2013 Dec; 9(12):2017-23. PubMed ID: 24266257
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel-loaded polylactic acid-co-glycolic acid nanoparticles: formulation, physicochemical characterization and cytotoxicity studies.
Pradhan R; Poudel BK; Ramasamy T; Choi HG; Yong CS; Kim JO
J Nanosci Nanotechnol; 2013 Aug; 13(8):5948-56. PubMed ID: 23882865
[TBL] [Abstract][Full Text] [Related]
17. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
Feng SS; Mei L; Anitha P; Gan CW; Zhou W
Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
[TBL] [Abstract][Full Text] [Related]
18. Improved mucoadhesion and cell uptake of chitosan and chitosan oligosaccharide surface-modified polymer nanoparticles for mucosal delivery of proteins.
Dyawanapelly S; Koli U; Dharamdasani V; Jain R; Dandekar P
Drug Deliv Transl Res; 2016 Aug; 6(4):365-79. PubMed ID: 27106502
[TBL] [Abstract][Full Text] [Related]
19. [Formulation and process optimization of doxorubicin-loaded PLGA nanoparticles and its in vitro release].
Li JL; Zheng CL; Liu JP; Zhu JB
Yao Xue Xue Bao; 2013 May; 48(5):759-66. PubMed ID: 23888702
[TBL] [Abstract][Full Text] [Related]
20. Poly aspartic acid peptide-linked PLGA based nanoscale particles: potential for bone-targeting drug delivery applications.
Jiang T; Yu X; Carbone EJ; Nelson C; Kan HM; Lo KW
Int J Pharm; 2014 Nov; 475(1-2):547-57. PubMed ID: 25194353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
